More about

Metastatic Prostate Cancer

News
February 06, 2020
2 min read
Save

Penn researchers receive grant to develop CAR-T for advanced prostate cancer

Penn researchers receive grant to develop CAR-T for advanced prostate cancer

Alliance for Cancer Gene Therapy awarded a $500,000 grant to researchers at University of Pennsylvania’s Abramson Cancer Center to develop new chimeric antigen receptor T-cell therapies for advanced metastatic prostate cancer.

News
January 15, 2020
1 min read
Save

FDA grants priority review to Rubraca for advanced prostate cancer

The FDA granted priority review to rucaparib for treatment of advanced prostate cancer, according to the agent’s manufacturer.

News
September 30, 2019
3 min read
Save

Cabazitaxel improves outcomes among certain men with metastatic prostate cancer

Cabazitaxel improves outcomes among certain men with metastatic prostate cancer

BARCELONA, Spain — Cabazitaxel significantly improved outcomes compared with androgen receptor-targeted therapies for certain men with previously treated metastatic castration-resistant prostate cancer, according to results of the randomized CARD study presented at European Society for Medical Oncology Congress.

News
September 27, 2019
3 min read
Save

Addition of docetaxel to androgren deprivation confers durable OS benefit for metastatic prostate cancer

Addition of docetaxel to androgren deprivation confers durable OS benefit for metastatic prostate cancer

BARCELONA, Spain — The addition of upfront docetaxel chemotherapy to androgen deprivation therapy conferred durable, clinically significant benefit for men with low- and high-burden metastatic prostate cancer, according to results of the randomized phase 3 STAMPEDE trial presented at European Society for Medical Oncology Congress.

News
September 18, 2019
2 min read
Save

FDA expands Erleada approval for prostate cancer

FDA expands Erleada approval for prostate cancer

The FDA expanded the approval of apalutamide to include treatment of men with metastatic castration-sensitive prostate cancer.

News
August 22, 2019
2 min read
Save

FDA grants priority review to Xtandi for metastatic hormone-sensitive prostate cancer

The FDA has granted priority review to enzalutamide for the treatment of men with metastatic hormone-sensitive prostate cancer, according to a press release from the drug’s manufacturer.

View more